Takayuki Tokunaga

6PUBLICATIONS
12CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 03, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Hiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto

|May 03, 2025
Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue

|Dec 22, 2023
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki

|Nov 29, 2023
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka

|Mar 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo

|Oct 09, 2021
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.

Takayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka

Pageof 1

Frequent Collaborators

5 joint publications

Hiroki Inada

5 joint publications

Yasuhito Tanaka

4 joint publications

Katsuya Nagaoka

2 joint publications

Kentaro Matsuura